Upgrade to SI Premium - Free Trial

SAB Biotherapeutics (SABS)

3.41 -0.05 (1.45%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/17/26)

Latest Headlines

Form 424B3 SAB Biotherapeutics, August 21, 2026 4:30 PM - SEC Filing Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC August 14, 2026 5:24 PM - SEC Filing Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Caligan Partners LP August 14, 2026 4:53 PM - SEC Filing Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Commodore Capital LP August 14, 2026 4:14 PM - SEC Filing Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P. August 14, 2026 4:13 PM - SEC Filing Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Woodline Partners LP August 14, 2026 11:04 AM - SEC Filing Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P. August 14, 2026 6:14 AM - SEC Filing Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Adage Capital Management, L.P. August 12, 2026 12:09 PM - SEC Filing Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. August 10, 2026 4:27 PM - SEC Filing Form 10-Q SAB Biotherapeutics, For: Jun 30 August 6, 2026 7:57 AM - SEC Filing Form 8-K SAB Biotherapeutics, For: Jul 07 July 7, 2026 8:15 AM - SEC Filing Form 4 SAB Biotherapeutics, For: Jun 25 Filed by: Kropotova Alexandra June 26, 2026 5:20 PM - SEC Filing Barclays Starts SAB Biotherapeutics (SABS) at Overweight June 24, 2026 6:20 AM - StreetInsider Form 8-K SAB Biotherapeutics, For: Jun 18 June 18, 2026 4:35 PM - SEC Filing Full Article List